IDH1 and central nervous system cancer: Several promising molecular targets have been identified, including mutant IDH, PDGFR, VEGFR, integrin αvβ3 receptor, EGFR, c-Met, etc., These molecules and their specific inhibitors have been studied in multiple trials, and we summarize the MI modalities that are being used to visualize them in the context of glioma therapy.